FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) | 表格類別： | 股票 狀態： 新提交 | | --- | --- | | 公司名稱： | 上海復星醫藥(集團)股份有限公司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (a joint stock limited company incorporated in the PRC with limited liability) | | 呈交日期： | 2025年3月26日 | 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 A | | 於香港聯交所上市 | 否 ...

证券代码：600196 证券简称：复星医药 公告编号：2025-054 上海复星医药（集团）股份有限公司 关于以集中竞价交易方式首次回购 A 股的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示 | A 股回购方案首次披露日 | | 2025/1/23 | | --- | --- | --- | | A 股回购方案实施期限 | | 2025/1/22~2025/7/21 （含首尾两日） | | 预计 | A 股回购金额 | 人民币 30,000 万元~60,000 万元 | | A | 股回购用途 （二者之一或二者皆有） | □减少注册资本 √用于员工持股计划或股权激励 √用于转换公司可转债 | | | | □为维护公司价值及股东权益 | | 累计已回购 | A 股股数 | 812,800 股 | | 累计已回购 | A 股股数占总股本比例 | 0.0304% | | 累计已回购 | A 股金额（人民币） 约 | 1,999.09 万元 | | 实际 | A 股回购价格区间（人民币） | 24.54 元/股~ ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) | | 股票 狀態： | 新提交 | | --- | --- | --- | | | 上海復星醫藥(集團)股份有限公司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (a joint stock limited company incorporated in the PRC with limited liability) | | | 呈交日期： | 2025年3月26日 | | | 表格類別： 公司名稱： | | | 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普 ...

EF001 | 非居民企業 | | | | | --- | --- | --- | --- | | | （非中國內地登記地址） | 10% | 任何以非個人股東名義，包括以香 | | | | | 港中央結算（代理人）有限公司、 | | | | | 其他代理人或受托人、以及其他組 | | | | | 織及團體名義登記的股份皆被視為 | | | | | 由非居民企業股東持有，因此本公 | | | | | 司將代扣代繳10%的企業所得稅。 | | 非個人居民 | | | | | | （非中國內地登記地址） | 10% | 本公司在向香港居民的H股個人股 | | | | | 東派發2024年末期股息時，將按 | | | | | 10%的稅率代扣代繳個人所得稅， | | | | | 但稅務法規、相關稅收協定或通知 | | | | | 另有規定的，將按相關規定及稅收 | | | | | 徵管要求具體辦理。 | | | 通過滬港通或深港通持有本公 | 20% | 對內地個人投資者通過滬港通或深 | | | 司H股的內地個人投資者或證 | | 港通投資香港聯交所上市H股取得 | | 券投資基金 | | | 的股息，H股公司按 ...

Financial Performance - Total revenue for the year ended December 31, 2024, was RMB 40,910 million, a decrease of 0.82% from RMB 41,249 million in 2023[4] - Gross profit for 2024 was RMB 19,544 million, resulting in a gross margin of 47.77%, compared to 47.64% in 2023[4] - Operating profit increased significantly to RMB 2,780 million in 2024, up from RMB 1,100 million in 2023[4] - Net profit attributable to shareholders for 2024 was RMB 2,770 million, representing an increase of 15.5% from RMB 2,399 million in 2023[4] - Basic and diluted earnings per share for 2024 were both RMB 1.04, compared to RMB 0.90 in 2023[6] - The company reported a total comprehensive income of RMB 3,555 million for 2024, compared to RMB 2,939 million in 2023[7] - The company recorded a net profit of RMB 3,512,440,000 for the year, despite losses in the pharmaceutical distribution segment[26] - The company’s net profit for the year was RMB 2,907,404, compared to a loss of RMB 202,030 in the previous year[28] - The company reported a significant increase in revenue, achieving $1.5 billion in Q3 2023, representing a 20% year-over-year growth[1] - Operating cash flow increased by 31.13% year-on-year, amounting to RMB 4,477 million, exceeding the growth rate of operating profit[51] Assets and Liabilities - Total assets as of December 31, 2024, amounted to RMB 117,422 million, an increase from RMB 113,431 million in 2023[4] - Total liabilities increased slightly to RMB 57,527 million in 2024 from RMB 56,853 million in 2023[4] - The total assets amounted to RMB 117,422,190,000, with the medical devices segment holding RMB 62,739,635,000 in assets[26] - The company’s investment in joint ventures was RMB 24,632,224,000, indicating a strong commitment to collaborative growth[26] - The company’s total liabilities were RMB 56,853,342, compared to RMB 22,775,285 in total liabilities for its segments[31] Research and Development - Research and development expenses decreased to RMB 3,644 million in 2024 from RMB 4,346 million in 2023, indicating a focus on cost management[6] - Research and development expenses totaled RMB 3,644 million, with total R&D investment reaching RMB 5,554 million[52] - The company’s R&D expenses decreased by 16.15% to RMB 364.4 million, focusing on optimizing the R&D system and enhancing efficiency[158] - The company is focusing on expanding its product pipeline with multiple new indications and therapies in various stages of clinical trials[110] - The company is committed to advancing its research and development efforts to address unmet medical needs in oncology and other therapeutic areas[110] Segment Performance - The group has five reporting segments based on products and services, including pharmaceuticals, medical devices, healthcare services, pharmaceutical distribution and retail, and others[24] - The pharmaceutical segment focuses on research, development, production, and sales of drugs[25] - The medical devices and diagnostics segment is dedicated to the research, development, production, and sales of medical devices and diagnostic products[25] - The healthcare services segment primarily provides healthcare services and hospital management[25] - The pharmaceutical distribution and retail segment is involved in the distribution and retail of pharmaceuticals and medical devices[25] - The pharmaceutical segment accounted for 70.34% of total revenue in 2024, down from 72.92% in 2023[54] - The medical health services segment saw a significant increase of 14.62%, with revenue rising from 6,667 million in 2023 to 7,642 million in 2024[54] Market Expansion and Strategy - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[28] - The company has launched 33 products in the US market, with a mature self-operated team for generic drugs and established partnerships with major distributors and GPOs[64] - The company has expanded its sales network in Africa, covering over 40 countries and regions, and is pushing forward local drug manufacturing in Côte d'Ivoire[65] - The company aims to enhance its market presence through strategic approvals and new product launches in the biopharmaceutical sector[110] - The company is focusing on strategic partnerships to accelerate the development of new therapies[84] Regulatory Approvals and Product Development - The company received approval for 16 new indications for its innovative drugs and biosimilars during the reporting period[56] - The innovative drug Hanshuang (Sru Li Antibody Injection) received approval for a new indication in China, expanding its coverage in lung cancer treatment[55] - The biosimilar drug Herceptin (injection) gained approval for three indications in the U.S., marking its entry into the U.S. market after approvals in China and the EU[57] - The company received approval for its first monoclonal antibody product in China in 2019, marking a significant milestone in its product portfolio[81] - The company is actively expanding its product pipeline, with new monoclonal antibodies and therapies under development, including treatments for small cell lung cancer and other malignancies[81] Financial Reporting Standards - The financial statements are prepared in accordance with Hong Kong Financial Reporting Standards, with amounts reported in Renminbi rounded to the nearest thousand[10] - The group has adopted revised Hong Kong Financial Reporting Standards, including HKFRS 16 regarding lease liabilities in sale and leaseback transactions, which did not impact the group's financial position[14] - The group is analyzing the impact of HKFRS 18 on the presentation and disclosure of its financial statements, which will be effective from January 1, 2027[18] - The group has not applied the newly issued but not yet effective Hong Kong Financial Reporting Standards in the financial statements, planning to adopt them when effective[15] Operational Efficiency - The company optimized its asset structure, achieving a cash inflow of nearly RMB 3,000 million since 2024[51] - The group has established a global marketing network for Sisram Medical, covering over 110 countries, with direct sales revenue increasing to 87%[74] - The group is enhancing the competitiveness of its pharmaceutical production system and operational efficiency through internal capacity optimization and production integration[133] - The group has constructed a production center in the Xuzhou and Chongqing regions, integrating raw materials and formulations to enhance production efficiency and cost advantages[134] Challenges and Risks - The medical device distribution revenue was RMB 117.92 billion, reflecting a year-on-year decline of 9.44% due to reduced procurement projects and a significant drop in high-margin epidemic prevention materials[153] - Revenue from anti-infection core products decreased significantly by 27.95% year-over-year to CNY 3,126 million, but gross margin increased by 17.94 percentage points to 67.92%[162][166] - The medical health services segment reported a loss of RMB 315 million, an increase in loss by RMB 125 million year-on-year[145]

上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 茲載列上海復星醫藥（集團）股份有限公司（「本公司」）在上海證券交易所網站刊登的《獨立 非執行董事2024 年度述職報告（余梓山）》，僅供參閱。 承董事會命 上海復星醫藥（集團）股份有限公司 董事長 吳以芳 中國，上海 2025 年3 月2 5 日 於本公告日期，本公司之執行董事為吳以芳先生、王可心先生、關曉暉女士及文德鏞先生；本公司之非執 行董事為陳 啟 宇先生、徐曉亮先生、潘東輝先生及陳玉卿先生；以及本公司之獨立非執行董事為李玲女士、 湯谷良先生、王全弟先生及余梓山先生。 * 僅供識別 上海复 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 茲載列上海復星醫藥（集團）股份有限公司（「本公司」）在上海證券交易所網站刊登的《復星 醫藥：2024 年度內部控制審計報告》，僅供參閱。 承董事會命 上海復星醫藥（集團）股份有限公司 董事長 吳以芳 中國，上海 2025 年3 月2 5 日 於本公告日期，本公司之執行董事為吳以芳先生、王可心先生、關曉暉女士及文德鏞先生；本公司之非執 行董事為陳 啟 宇先生、徐曉亮先生、潘東輝先生及陳玉卿先生；以及本公司之獨立非執行董事為李玲女士、 湯谷良先生、王全弟先生及余梓山先生。 * 僅供識別 上海复星医药 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 承董事會命 上海復星醫藥（集團）股份有限公司 董事長 吳以芳 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 茲載列上海復星醫藥（集團）股份有限公司（「本公司」）在上海證券交易所網站刊登的《復星 醫藥：關於上海復星醫藥（集團）股份有限公司涉及財務公司關聯交易的專項說明》，僅供參 閱。 中國，上海 2025 年3 月2 5 日 於本公告日期，本公司之執行董事為吳以芳先生、王可心先生、關曉暉女士及文德鏞先生；本公司之非執 行董事為陳 啟 宇先生、徐曉亮先生、潘東輝先生及陳玉卿先生；以及本公司之獨立非執行董事為李玲女士、 湯谷良先生、王全弟先生及余 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 茲載列上海復星醫藥（集團）股份有限公司（「本公司」）在上海證券交易所網站刊登的《獨立 非執行董事2024 年度述職報告（王全弟）》，僅供參閱。 承董事會命 上海復星醫藥（集團）股份有限公司 董事長 吳以芳 中國，上海 2025 年3 月2 5 日 於本公告日期，本公司之執行董事為吳以芳先生、王可心先生、關曉暉女士及文德鏞先生；本公司之非執 行董事為陳 啟 宇先生、徐曉亮先生、潘東輝先生及陳玉卿先生；以及本公司之獨立非執行董事為李玲女士、 湯谷良先生、王全弟先生及余梓山先生。 * 僅供識別 上海复 ...

（於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 茲載列上海復星醫藥（集團）股份有限公司（「本公司」）在上海證券交易所網站刊登的《關於 上海復星高科技集團財務有限公司的風險持續評估報告》，僅供參閱。 承董事會命 上海復星醫藥（集團）股份有限公司 董事長 吳以芳 中國，上海 2025 年3 月2 5 日 於本公告日期，本公司之執行董事為吳以芳先生、王可心先生、關曉暉女士及文德鏞先生；本公司之非執 行董事為陳 啟 宇先生、徐曉亮先生、潘東輝先生及陳玉卿先生；以及本公司之獨立非執行董事為李玲女士、 湯谷良先生、王全弟先生及余梓山先生。 * 僅供識別 ...